Emanuele Zucca
A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers.
Spriano F, Sartori G, Sgrignani J, Barnabei L, Arribas A, Guala M, Del Amor A, Tomasso M, Tarantelli C, Cascione L, Golino G, Riveiro M, Bortolozzi R, Lupia A, Paduano F, Huguet S, Rezai K, Rinaldi A, Margheriti F, Ventura-Aguiar P, Guarda G, Costa G, Rocca R, Furlan A, Verdonk L, Innocenti P, Martin N, Viola G, Driessen C, Zucca E, Stathis A, Gahtory D, Van den Nieuwboer M, Bornhauser B, Alcaro S, Trapasso F, Cristobal S, Padrick S, Pazzi N, Cavalli F, Cavalli A, Gaudio E, Bertoni F. A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers. Haematologica 2024
Jun 20, 2024A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers.
Jun 20, 2024Haematologica 2024
Spriano Filippo, Sartori Giulio, Sgrignani Jacopo, Barnabei Laura, Arribas Alberto, Guala Matilde, Del Amor Ana Maria Carrasco, Tomasso Meagan R, Tarantelli Chiara, Cascione Luciano, Golino Gaetanina, Riveiro Maria E, Bortolozzi Roberta, Lupia Antonio, Paduano Francesco, Huguet Samuel, Rezai Keyvan, Rinaldi Andrea, Margheriti Francesco, Ventura-Aguiar Pedro, Guarda Greta, Costa Giosuè, Rocca Roberta, Furlan Alberto, Verdonk Luuk M, Innocenti Paolo, Martin Nathaniel I, Viola Giampietro, Driessen Christoph, Zucca Emanuele, Stathis Anastasios, Gahtory Digvijay, Van den Nieuwboer Maurits, Bornhauser Beat, Alcaro Stefano, Trapasso Francesco, Cristobal Susana, Padrick Shae B, Pazzi Natalina, Cavalli Franco, Cavalli Andrea, Gaudio Eugenio, Bertoni Francesco
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova V, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C. Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). EClinicalMedicine 2023; 64:102221.
Sep 22, 2023Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Sep 22, 2023EClinicalMedicine 2023; 64:102221
Novak Urban, Fehr Martin, Schär Sämi, Dreyling Martin, Schmidt Christian, Derenzini Enrico, Zander Thilo, Hess Georg, Mey Ulrich J M, Ferrero Simone, Mach Nicolas, Boccomini Carola, Böttcher Sebastian, Voegeli Michèle, Cairoli Anne, Ivanova Vanesa-Sindi, Menter Thomas, Dirnhofer Stefan, Scheibe Bernhard, Gadient Sandra, Eckhardt Katrin, Zucca Emanuele, Driessen Christoph, Renner Christoph
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Adv 2022; 6:3911-3920.
Jul 12, 2022SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Jul 12, 2022Blood Adv 2022; 6:3911-3920
Stathis Anastasios, Mey Ulrich, Schär Sämi, Hitz Felicitas, Pott Christiane, Mach Nicolas, Krasniqi Fatime, Novak Urban, Schmidt Christian, Hohloch Karin, Kienle Dirk, Hess Dagmar, Moccia Alden A, Unterhalt Michael, Eckhardt Katrin, Hayoz Stefanie, Forestieri Gabriela, Rossi Davide, Dirnhofer Stefan, Ceriani Luca, Sartori Giulio, Bertoni Francesco, Buske Christian, Zucca Emanuele, Hiddemann Wolfgang
Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Pirosa M, Cittone M, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista M, Bastidas G, Beà S, Boldorini R, Broccoli A, Buehler M, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia A, Facchetti F, Gaidano G, Garcia J, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, López-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier D, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabattini E, Salles G, Santambrogio E, Scarfo L, Stathis A, Stussi G, Geyer J, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani P, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, de Leval L, Dirnhofer S, Pileri S, Piris M, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood 2022; 139:732-747.
Feb 3, 2022Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Feb 3, 2022Blood 2022; 139:732-747
Bonfiglio Ferdinando, Bruscaggin Alessio, Guidetti Francesca, Terzi di Bergamo Lodovico, Faderl Martin Richard, Spina Valeria, Condoluci Adalgisa, Bonomini Luisella, Forestieri Gabriela, Koch Ricardo, Piffaretti Deborah, Pini Katia, Pirosa Maria Cristina, Cittone Micol Giulia, Arribas Alberto, Lucioni Marco, Ghilardi Guido, Wu Wei, Arcaini Luca, Baptista Maria Joao, Bastidas Gabriela, Beà Silvia, Boldorini Renzo, Broccoli Alessandro, Buehler Marco, Canzonieri Vincenzo, Cascione Luciano, Ceriani Luca, Cogliatti Sergio, Corradini Paolo, Derenzini Enrico, Devizzi Liliana, Dietrich Sascha, Elia Angela Rita, Facchetti Fabio, Gaidano Gianluca, Garcia Juan Fernando, Gerber Bernhard, Ghia Paolo, Gomes da Silva Maria, Gritti Giuseppe, Guidetti Anna, Hitz Felicitas, Inghirami Giorgio, Ladetto Marco, López-Guillermo Armando, Lucchini Elisa, Maiorana Antonino, Marasca Roberto, Matutes Estella, Meignin Véronique, Merli Michele, Moccia Alden, Mollejo Manuela, Montalban Carlos, Novak Urban, Oscier David Graham, Passamonti Francesco, Piazza Francesco A, Pizzolitto Stefano, Rambaldi Alessandro, Sabattini Elena, Salles Gilles Andre, Santambrogio Elisa, Scarfo Lydia, Stathis Anastasios, Stussi Georg, Geyer Julia Turbiner, Tapia Gustavo, Tarella Corrado, Thieblemont Catherine, Tousseyn Thomas, Tucci Alessandra, Vanini Giorgio, Visco Carlo, Vitolo Umberto, Walewska Renata, Zaja Francesco, Zenz Thorsten, Zinzani Pier Luigi, Khiabanian Hossein, Calcinotto Arianna, Bertoni Francesco, Bhagat Govind, Campo Elias, de Leval Laurence, Dirnhofer Stefan, Pileri Stefano A, Piris Miguel A, Traverse-Glehen Alexandra, Tzankov Alexander, Paulli Marco, Ponzoni Maurilio, Mazzucchelli Luca, Cavalli Franco, Zucca Emanuele, Rossi Davide
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Pirosa M, Zhang L, Hitz F, Novak U, Hess D, Terrot T, Pascale M, Mazzucchelli L, Bertoni F, Cavalli F, Zucca E, Stathis A. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Leuk Lymphoma 2021; 63:117-123.
Aug 19, 2021A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Aug 19, 2021Leuk Lymphoma 2021; 63:117-123
Pirosa Maria C, Zhang Lu, Hitz Felicitas, Novak Urban, Hess Dagmar, Terrot Tatiana, Pascale Mariarosa, Mazzucchelli Luca, Bertoni Francesco, Cavalli Franco, Zucca Emanuele, Stathis Anastasios
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial
Moccia A, Rauch D, Vorobiof D, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Raats J, Del Giglio A, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Zucca E. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Adv 2020; 4:5951-5957.
Dec 8, 2020Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial
Dec 8, 2020Blood Adv 2020; 4:5951-5957
Moccia Alden A, Rauch Daniel, Vorobiof Daniel A, Lohri Andreas, Ruegsegger Céline, Biaggi Rudolf Christine, Rusterholz Corinne, Hayoz Stefanie, Ghielmini Michele, Raats Johann, Del Giglio Auro, Taverna Christian, Schär Sämi, Vanazzi Anna, Rondeau Stephanie, Hitz Felicitas, Mingrone Walter, Pabst Thomas, Cevreska Lidija, Zucca Emanuele
Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy
Menter T, Hayoz S, Hawle H, Sander B, Mazzucchelli L, Grobholz R, Karjalainen-Lindsberg M, Cathomas G, Banz Y, Cogliatti S, Beiske K, Sundstrom C, Hultdin M, Kimby E, Zucca E, Tzankov A, Dirnhofer S. Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. Br J Haematol 2020; 189:707-717.
Feb 3, 2020Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy
Feb 3, 2020Br J Haematol 2020; 189:707-717
Menter Thomas, Hayoz Stefanie, Hawle Hanne, Sander Birgitta, Mazzucchelli Luca, Grobholz Rainer, Karjalainen-Lindsberg Marja-Liisa, Cathomas Gieri, Banz Yara, Cogliatti Sergio B., Beiske Klaus, Sundstrom Christer, Hultdin Magnus, Kimby Eva, Zucca Emanuele, Tzankov Alexandar, Dirnhofer Stefan
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Zucca E, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei S, Ghielmini M, Kimby E, Novak U, Lohri A, Ferreri A, Rondeau S, Vanazzi A, Østenstad B, Mey U, Rauch D, Wahlin B, Hitz F, Hernberg M, Johansson A, de Nully Brown P, Hagberg H, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood 2019; 134:353-362.
May 17, 2019Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
May 17, 2019Blood 2019; 134:353-362
Zucca Emanuele, Zander Thilo, Bersvendsen Hanne, Bargetzi Mario, Mingrone Walter, Krasniqi Fatime, Dirnhofer Stefan, Hayoz Stefanie, Hawle Hanne, Vilei Simona Berardi, Ghielmini Michele, Kimby Eva, Novak Urban, Lohri Andreas, Ferreri Andrés J M, Rondeau Stephanie, Vanazzi Anna, Østenstad Bjørn, Mey Ulrich J M, Rauch Daniel, Wahlin Björn E, Hitz Felicitas, Hernberg Micaela, Johansson Ann-Sofie, de Nully Brown Peter, Hagberg Hans, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group
Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals
Conconi A, Bernasconi E, Bertoni F, Gaidano G, Cavalli F, Nassi L, Kwee I, Dirnhofer S, Scherrer A, Schmid P, Novak U, Staehelin C, Battegay M, Hasse B, Darling K, Margiotta-Casaluci G, Zucca E, Swiss HIV Cohort Study (SHCS). Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. Hematol Oncol 2018
Aug 16, 2018Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals
Aug 16, 2018Hematol Oncol 2018
Conconi Annarita, Bernasconi Enos, Bertoni Francesco, Gaidano Gianluca, Cavalli Franco, Nassi Luca, Kwee Ivo, Dirnhofer Stephan, Scherrer Alexandra, Schmid Patrick, Novak Urban, Staehelin Cornelia, Battegay Manuel, Hasse Barbara, Darling Katharine, Margiotta-Casaluci Gloria, Zucca Emanuele, Swiss HIV Cohort Study (SHCS)
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions
Gobba S, Gaidano G, Pinotti G, Hitz F, Stathis A, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Iacoboni G, Cascione L, Diem S, Conconi A, Gulden-Sala W, Moccia A, Zucca E. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions. Hematol Oncol 2017
Jun 16, 2017Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions
Jun 16, 2017Hematol Oncol 2017
Gobba Stefania, Gaidano Gianluca, Pinotti Graziella, Hitz Felicitas, Stathis Anastasios, Aprile von Hohenstaufen Kathrin, Margiotta-Casaluci Gloria, Iacoboni Gloria, Cascione Luciano, Diem Stefan, Conconi Annarita, Gulden-Sala Wiebke, Moccia Alden A, Zucca Emanuele
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
Hitz F, Rondeau S, Berardi Vilei S, Eckhardt K, Enoiu M, Rothermundt C, Schmidt A, Krasniqi F, Mach N, Caspar C, Samaras P, Cairoli A, Fischer N, Pabst T, Zucca E, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Br J Haematol 2016
Mar 28, 2016Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
Mar 28, 2016Br J Haematol 2016
Hitz Felicitas, Rondeau Stephanie, Berardi Vilei Simona, Eckhardt Katrin, Enoiu Milica, Rothermundt Christian, Schmidt Adrian, Krasniqi Fatime, Mach Nicolas, Caspar Clemens B, Samaras Panagiotis, Cairoli Anne, Fischer Natalie, Pabst Thomas, Zucca Emanuele, Mey Ulrich
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
Taverna C, Zucca E, Heijnen I, Rusterholz C, Rondeau S, Biaggi Rudolf C, Lohri A, Vorobiof D, Rauch D, Raats J, Laszlo D, Vanazzi A, Del Giglio A, Cevreska L, Pabst T, Mingrone W, Hitz F, Martinelli G, Ghielmini M. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. J Clin Oncol 2015; 34:495-500.
Dec 28, 2015Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
Dec 28, 2015J Clin Oncol 2015; 34:495-500
Taverna Christian, Zucca Emanuele, Heijnen Ingmar A F M, Rusterholz Corinne, Rondeau Stephanie, Biaggi Rudolf Christine, Lohri Andreas, Vorobiof Daniel A, Rauch Daniel, Raats Johann, Laszlo Daniele, Vanazzi Anna, Del Giglio Auro, Cevreska Lidija, Pabst Thomas, Mingrone Walter, Hitz Felicitas, Martinelli Giovanni, Ghielmini Michele
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Mamot C, Zucca E, Dirnhofer S, Rusterholz C, Biaggi C, Samarin A, Hany T, Gigli F, Krasniqi F, Bargetzi M, Pless M, Mey U, Driessen C, Pabst T, Renner C, Hitz F, Klingbiel D, Martinelli G. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). J Clin Oncol 2015; 33:2523-9.
Jul 6, 2015Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Jul 6, 2015J Clin Oncol 2015; 33:2523-9
Mamot Christoph, Zucca Emanuele, Dirnhofer Stephan, Rusterholz Corinne, Biaggi Christine, Samarin Andrei, Hany Thomas, Gigli Federica, Krasniqi Fatime, Bargetzi Mario, Pless Miklos, Mey Ulrich, Driessen Christoph, Pabst Thomas, Renner Christoph, Hitz Felicitas, Klingbiel Dirk, Martinelli Giovanni
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Chigrinova E, Ladetto M, Forconi F, Cogliatti S, Votavova H, Swerdlow S, Stilgenbauer S, Piris M, Matolcsy A, Spagnolo D, Nikitin E, Zamò A, Gattei V, Bhagat G, Ott G, Zucca E, Gaidano G, Inghirami G, Marasca R, Rinaldi A, Kwee I, Rossi D, Rancoita P, Strefford J, Oscier D, Stamatopoulos K, Papadaki T, Berger F, Young K, Murray F, Rosenquist R, Greiner T, Chan W, Orlandi E, Lucioni M, Bertoni F. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 2013; 122:2673-82.
Sep 4, 2013Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Sep 4, 2013Blood 2013; 122:2673-82
Chigrinova Ekaterina, Ladetto Marco, Forconi Francesco, Cogliatti Sergio B., Votavova Hana, Swerdlow Steven H, Stilgenbauer Stephan, Piris Miguel A, Matolcsy Andras, Spagnolo Dominic, Nikitin Eugene, Zamò Alberto, Gattei Valter, Bhagat Govind, Ott German, Zucca Emanuele, Gaidano Gianluca, Inghirami Giorgio, Marasca Roberto, Rinaldi Andrea, Kwee Ivo, Rossi Davide, Rancoita Paola M V, Strefford Jonathan C, Oscier David, Stamatopoulos Kostas, Papadaki Theodora, Berger Françoise, Young Ken H, Murray Fiona, Rosenquist Richard, Greiner Timothy C, Chan Wing C, Orlandi Ester M, Lucioni Marco, Bertoni Francesco
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma
Rinaldi A, Rossi D, Gaidano G, Zucca E, Cavalli F, Cogliatti S, Berger F, Marasca R, Gattei V, Lucioni M, Orlandi E, Forconi F, Kwee I, Mensah A, Bertoni F. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. Br J Haematol 2013; 163:194-204.
Aug 21, 2013Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma
Aug 21, 2013Br J Haematol 2013; 163:194-204
Rinaldi Andrea, Rossi Davide, Gaidano Gianluca, Zucca Emanuele, Cavalli Franco, Cogliatti Sergio B., Berger Françoise, Marasca Roberto, Gattei Valter, Lucioni Marco, Orlandi Ester M, Forconi Francesco, Kwee Ivo, Mensah Afua Adjeiwaa, Bertoni Francesco
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
Wannesson L, Samaras P, Renner C, Pabst T, Lerch E, Hess U, Heim D, Cerutti A, Cairoli A, Bargetzi M, Zucca E. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leuk Lymphoma 2012; 54:36-40.
Jul 9, 2012Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
Jul 9, 2012Leuk Lymphoma 2012; 54:36-40
Wannesson Luciano, Samaras Panagiotis, Renner Christoph, Pabst Thomas, Lerch Erika, Hess Urs, Heim Dominik, Cerutti Alessandra, Cairoli Anne, Bargetzi Mario, Zucca Emanuele
Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
Jörger M, Ferreri A, Krähenbühl S, Schellens J, Cerny T, Zucca E, Huitema A. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol 2012; 73:240-7.
Feb 1, 2012Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
Feb 1, 2012Br J Clin Pharmacol 2012; 73:240-7
Jörger Markus, Ferreri Andrés J M, Krähenbühl Stephan, Schellens Jan H M, Cerny Thomas, Zucca Emanuele, Huitema Alwin D R
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof D, Heizmann M, Stahel R, Stupp R, Okkinga E, Bassi S, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4.
Aug 9, 2010Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Aug 9, 2010J Clin Oncol 2010; 28:4480-4
Martinelli Giovanni, Zucca Emanuele, Dietrich Pierre-Yves, Lohri Andreas, Vorobiof Daniel, Heizmann Marc, Stahel Rolf, Stupp Roger, Okkinga Emmie, Bassi Simona, Hess Urs, Cerny Thomas, Utiger Urs, Schmitz Shu-Fang Hsu, Ghielmini Michele
A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function
Siano M, Gallino A, Sessa C, Mora O, Leoncini L, Oberson M, Rodriguez-Abreu D, Zucca E, Negretti L, Lerch E, Ghielmini M. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clinical cancer research : an official journal of the American Association for Cancer Research 2008; 14:7935-9.
Dec 1, 2008A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function
Dec 1, 2008Clinical cancer research : an official journal of the American Association for Cancer Research 2008; 14:7935-9
Siano Marco, Gallino Augusto, Sessa Cristiana, Mora Oreste, Leoncini Leda, Oberson Michel, Rodriguez-Abreu Delvys, Zucca Emanuele, Negretti Laura, Lerch Erika, Ghielmini Michele
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Ghielmini M, Vorobiof D, Bargetzi M, Lohri A, Helg C, Kovacsovics T, Stupp R, Zucca E, Hess U, Peccatori F, Martinelli G, Betticher D, Fey M, Waltzer U, Hummerjohann J, Pichert G, Cogliatti S, Schmitz S, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-23.
Jun 15, 2004Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Jun 15, 2004Blood 2004; 103:4416-23
Ghielmini Michele, Vorobiof Daniel, Bargetzi Mario, Lohri Andreas, Helg Claudine, Kovacsovics Tibor, Stupp Roger, Zucca Emanuele, Hess Urs, Peccatori Fedro, Martinelli Giovanni, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Hummerjohann Jörg, Pichert Gabriella, Cogliatti Sergio B, Schmitz Shu-Fang Hsu, Cerny Thomas